RSPO4-CRISPR alleviates liver injury and restores gut microbiota in a rat model of liver fibrosis

Linghua Yu, Linlin Wang, Xiaojun Wu & Huixing Yi

Wnt signaling dysfunction and gut dysbiosis may lead to liver fibrosis, yet the underlying mechanisms are not well elucidated. This study demonstrated the role of RSPO4, a Wnt signaling agonist, in liver fibrogenesis and its impact on the gut microbiome. RSPO4 gene in CCl4-induced fibrotic-liver rats was knockout by Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system, with healthy rats served as the control. Tissue samples and hepatic stellate cells (HSCs) isolated from rats were examined for curative effect of RSPO4-CRISPR treatment. Fecal sample were collected and analyzed with 16S rRNA sequencing. We found RSPO4-CRISPR relieved liver fibrosis in rats and reversed HSC activation. Further, results showed RSPO4-CRISPR tended to restore the microbiota composition. Significance species between groups were identified. Bacteroides and Escherichia-Shigella were the key microbes in the model and negative group, whereas Lactobacillus, Romboutsia, and Lachnospiraceae NK4A136 group were abundant in the control. Notably, Bacteroidales S24-7 group and Ruminococcaceae UCG-005 were the significantly enriched in CRISPR group. We show that the microbiome of rats treated with RSPO4-CRISPR presents a trend towards the restoration of the original condition. Our findings pave a new way to evaluate the curative effect of liver fibrosis treatment.
Liver fibrosis, a reversible wound-healing response to various forms of liver injury, is an increasing worldwide health burden.1–3 The advanced stage of liver fibrosis, known as cirrhosis, is a highly fatal disease with limited therapeutic options.4–6 Thus, finding effective therapies and non-invasive detection of liver fibrosis in early stages is a tremendous medical challenge.

Gut microbiota has a direct impact on metabolism, immunity, and response to infection in humans. Liver disease is associated with gut dysbiosis and prior studies have revealed alterations in gut microbiota in patients with liver fibrosis and found that dysbiotic changes in the gut microbiota contribute to the pathogenesis of liver disorder.1–3 The liver receives nutrients from the intestinal circulation via the portal vein, making it the first target of the gut microbiota.8 In healthy individuals, the intestinal mucosa acts as the “gut barrier” against the translocation of bacteria and microbial-derived products. Upon gut dysbiosis, the barrier dysfunction and alterations of the gut microbiota will cause liver injury and contribute to the progression of hepatic disease.8,9

Following liver injury, multiple intracellular signaling pathways drive hepatic stellate cell (HSC) activation, a crucial step in liver fibrogenesis. Numerous studies have shown that Wnt pathway activation is the central event of liver fibrogenesis.11 Roof plate-specific spondin 4 (RSPO4), which is involved in a broad range of developmental and physiological processes, is a Wnt pathway potentiator,8,9 and prior studies have shown that enrichment of RSPO4 induces epithelial proliferation and leads to enlargement of the mouse gastrointestinal tract.10,11 Although we have previously demonstrated that RSPO1/2/3 is correlated with liver fibrosis,12 the role of RSPO4 in liver fibrogenesis and its impact on the gut microbiome has not been well defined.

In the present study, we knocked out the RSPO4 gene in rats with CCl4-induced liver fibrosis using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system. The impact of RSPO4 knockout on the gut microbiome was investigated with 16 S rRNA sequencing. This study aimed to identify a panel of significant gut microbial species associated with liver fibrosis and its regression to normal status by controlling the underlying causes, which could be used to evaluate the therapeutic effectiveness of liver fibrosis treatments.

**Results**

**RSPO4-CRISPR reverses liver fibrogenesis in rats.** To investigate the role of RSPO4 in liver fibrogenesis, a rat model of liver fibrosis induced by CCl4 was established (Fig. 1a, b). CCl4-induced liver-fibrotic rats (the model group) were selected for in vivo transduction of lentivirus-expressing RSPO4-CRISPR (the CRISPR group) and CRISPR-NC (the negative group). Normal rats without any treatment served as the control. Liver tissues of rats were analyzed by Masson staining and Hematoxylin and eosin (H&E) staining. Masson staining of the rat liver tissues revealed that RSPO4-CRISPR may slow down liver fibrogenesis (Fig. 1A). Notably, the staining results showed the liver tissues of the CRISPR group tended to return to a normal status (similar to the control), and there was no significant difference between the model group and the negative group. Similar pattern could also be found in the HE staining (Fig. 1B). The recovering of vacuoles degeneration in the liver tissues of the CRISPR group was observed, which indicated that the knockout of RSPO4 might relieve the liver tissue injury. Consistent with the above findings, the results of PCR test (Fig. 1C) showed the mRNA levels of RSPO4, fibrosis biomarkers (α-SMA and collagen-I) in the CRISPR group decreased significantly compared with the model group and the negative group (p < 0.01 for RSPO4, α-SMA, and collagen-I). A noteworthy finding was that the mRNA levels of RSPO4, α-SMA, and collagen-I in the CRISPR group are likely to close to those of the control, suggesting RSPO4-CRISPR may be able to reverse the progression of liver fibrosis. Protein expression of RSPO4, α-SMA, and collagen-I (Fig. 1D) was examined by western blot assay. Aligned with the results of RT-PCR, the protein expressions of RSPO4, α-SMA, and collagen-I were notably weakened in the CRISPR group compared with the model group and the negative group. Together, these findings suggest that RSPO4-CRISPR may relieve liver fibrogenesis in rats.

The community α-diversity of CRISPR group is significantly higher than that of the model and similar to control. Fecal samples of rats were collected from the CRISPR group (20 rats), the negative group (20 rats), the model (20 rats), and the control (20 rats). 16 S rRNA gene amplicon sequencing was performed on the DNA extracted from the 80 fecal samples. In all, 16 S rRNA sequences reads with high quality were obtained from the 80 samples with an average of 54,225 sequences per sample (the minimum of one sample was 48,977 reads and the maximum was 57,890 reads).

Rarefaction curves for Shannon index tended to be smooth, which suggests a reasonable number of samples have been taken (Fig. 4A). Further, we observed from the rarefaction curves that
the model group and the negative group had lower community diversity (Shannon index) than the CRISPR group and the control. Species richness and evenness of each sample was visualized with rank abundance curves (Fig. 4B). Aligned with the results of rarefaction curves, rank abundance curves indicated the CRISPR group showed higher species richness and evenness than the model group and was similar to those of the control. Alpha diversity ($\alpha$-diversity) indexes of each sample were calculated. Results showed the community richness (Ace index) of the CRISPR group and the control were significantly higher than the model group and the negative group ($p < 0.01$ for both the CRISPR group and the control) and the negative group ($p < 0.05$ for both the CRISPR group and the control) (Fig. 4C). Moreover, there was no statistical difference between the CRISPR group and the control in the Ace index ($p = 0.12$). Consistent with the community richness, results demonstrated the community diversity (Shannon index) of the CRISPR group and the control were significantly higher than the model group ($p < 0.01$ for both the CRISPR group and the control) and the negative group ($p < 0.05$ for both the CRISPR group and the control) (Fig. 4D). No statistical difference in Shannon index was found between the CRISPR group and the control ($p = 0.48$). Together, the above findings suggested the gut microbiota diversity of the CRISPR group increased compared with the model group and tended to be similar to the control.

Liver fibrosis leads to gut microbiota dysbiosis, and RSPO4-CRISPR tends to restore the microflora composition to an equilibrium status, similar to the control. To reveal the phylogenetic relationship of taxonomy in the gut microflora of rats, a phylogenetic tree with number of reads per genus was constructed (Fig. 5A). Overall, results showed Lactobacillus (238,341 reads) had the highest abundance, followed by Escherichia–Shigella (223,949 reads), Bacteroides (216,570 reads), and Bacteroi-dales S24-7 group (208,292 reads).

According to the results of taxonomic analysis, the community composition of the model group, the negative group, the CRISPR group, and the control at the genus level was obtained (Fig. 5B). Results showed a distinct difference in gut microbiota community structure among groups. Overall, the model and the negative group shared a similar community composition pattern. Escherichia–Shigella had the highest abundance in the model group (16.7%) and the negative group (14.7%), and was followed by Lactobacillus (25.2%), Bacteroidales S24-7 group (9.1%), Lachnospiraceae NK4A136 group (8.5%) were the dominant genera in the control. Similarly, Bacteroidales S24-7 group (11.3%), Lactobacillus (7%), and unclassified Lachnospiraceae (5.7%) were prevalent in the CRISPR group. Interestingly, the community composition plot showed that the CRISPR group had a different gut microbiota structure than the model group and tended to be similar to the control.

Multivariate analyses were applied to illustrate the overall community structure of gut microbiota among all fecal samples.
Principal coordinates analysis (PCoA) was performed to visualize the difference in bacteria composition among groups (Fig. 5C). The first two components accounted for 33.28% (PC1: 21.94%, PC2: 11.34%) of the total variation. Four distinct groups that represented the model group, the negative group, the CRISPR group, and the control were identified. The control was obviously distinct from the model group and the negative group, and the CRISPR group intersected with the model group and the control.

By clustering the samples with similar dominant microbiota structures into one class, the microbiota typing analysis revealed two distinct enterotypes: type 1 and type 2 (Fig. 5D). Type 1 mainly consisted of samples from the model group, the negative group, and the CRISPR group, whereas type 2 mostly included samples from the control. Consistent with the findings in the PCoA analysis, samples from the CRISPR group were distributed in both type 1 and type 2. Together, the above findings showed the gut microbiota composition of the model group is apparently different from that of the control with lower diversity, which was consistent with previous studies reporting that liver fibrosis leads to gut microbiota dysbiosis.

Identification of species that significantly differ between the CRISPR, model, and control groups. The corresponding relationships between the abundance of species and samples were analyzed by Circos plot (Fig. 6A). The co-occurrence graph clearly demonstrated the proportion of dominant species in each group (the model group, the negative group, the CRISPR group, and the control) and the distribution proportion of groups in the predominant species. *Lactobacillus*, *Bacteroidales S24-7 group*, *Escherichia–Shigella*, *Bacteroides*, *Lachnospiraceae NK4A136 group*, *unclassified Lachnospiraceae*, *Romboutsia*, and *Ruminococcaceae UCG-014* were the predominant species in samples at the genus level. *Escherichia–Shigella* (the model group: 48%, the negative group: 42%, the CRISPR group: 9.6%, the control: 0.34%) and *Bacteroides* (the model group: 44%, the negative group: 41%, the CRISPR group: 13%, the control: 2%) were most abundant in the model and negative group, whereas *Lactobacillus* (the model group: 3.3%, the negative group: 9.7%, the CRISPR group: 19%, the control: 68%), *Lachnospiraceae NK4A136 group* (the model group: 11%, the negative group: 19%, the CRISPR group: 25%, the control: 45%) and *Romboutsia* (the model group: 9%, the negative group: 13%, the CRISPR group: 22%, the control: 56%) was predominant in the control. *Bacteroidales S24-7 group* (the model group: 19%, the negative group: 17%, the CRISPR group: 35%, the control: 28%) and *unclassified Lachnospiraceae* (the model group: 15%, the
were enriched in both the CRISPR group and the control. The significant differences between the groups were analyzed via Kruskal–Wallis H test (Fig. 6B). Results were consistent with those of the Circos analysis. Several significant species were identified. *Escherichia–Shigella* and *Bacteroides* (*p < 0.01*) were significantly enriched in the model and negative group, Bacteroidales S24-7 group and Lachnospiraceae NK4A136 group were abundant in both the CRISPR group and the control (*p < 0.01*), and *Lactobacillus* and *Romboutsia* were predominant in the control (*p < 0.01*). Compared with the model group (Wilcoxon rank-sum test), genera *Escherichia–Shigella*, *Bacteroides*, and Collinsella (*p < 0.01*) were decreased in the CRISPR group, whereas Bacteroidales S24-7 group, *Lactobacillus*, and Lachnospiraceae NK4A136 group were increased in the CRISRP group. Notably, there was almost no difference between the model and the negative group.

To identify bacteria that were specific for the groups, linear discriminant analysis of the fecal microbiota was performed (Fig. 6C). LEfSe (Linear discriminant analysis Effect Size) results were aligned with those of significant differences analysis. Overall, the abundances of 94 genera were significantly different between the groups. Twenty-three genera were more abundant in the model group, including *Escherichia–Shigella* (LDA = 4.88), *Bacteroides* (LDA = 4.83), Collinsella (LDA = 4.45), Allobaculum (LDA = 4.18), and Blautia (4.06), which indicated that these bacteria positively responded to the liver injury. Besides, *Lactobacillus* (LDA = 5.06), *Romboutsia* (LDA = 4.51), Lachnospiraceae NK4A136 group (LDA = 4.49), and Ruminococcaceae UCG_014 (LDA = 4.17) were higher in the control. Interestingly, 21 genera were significantly enriched in the CRISPR group, including Ruminococcaceae UCG_005 (LDA = 4.1), *Ruminococcus* (LDA = 3.91), and Ruminococcaceae UCG_013 (LDA = 3.76), which suggested these bacteria showed a positive response to the RSPO4-CRISPR injection.
The gut microbiome has emerged as a critical participant in the pathophysiology of many diseases. The gut microbiota promotes the development of intestinal diseases, as in inflammatory bowel disease and recurrent Clostridioides difficile infections, via local effects. Further, researches reveal the correlation between the gut microbiota and diseases at distant sites such as the liver and brain, via the gut–liver axis and gut–brain axis, respectively. Prior studies have reported that liver disorders associate with an altered microbiome, but few of them focused on the alteration of the microbiome before and after liver fibrosis treatment. In our study, liver fibrosis in rats was relieved by knockout of the RSPO4 gene with the CRISPR system. The gut microbiome of rats before and after the treatment was analyzed by 16S rRNA sequencing. Data showed that liver fibrosis is accompanied by gut dysbiosis, with low community α-diversity, and pathogenic bacteria dominate the bacterial community. Conversely, the treatment of RSPO4-CRISPR tended to restore the gut microflora to an equilibrium status similar to that of the healthy rat. This study also identified a group of significant taxa associated with liver fibrosis and its regression to normal status by treatment with RSPO4-CRISPR. We propose that this panel of significant taxa with other indices, such as the α-diversity and enterotype, can be a potential surveillance index for the therapeutic effectiveness of liver fibrosis treatment.

Liver fibrosis is an increasing worldwide health problem. Cirrhosis, the advanced stage of liver fibrosis, is among the most common causes of mortality worldwide and a significant risk factor of hepatocellular carcinoma. Fortunately, increasing evidence shows that liver fibrosis, and even cirrhosis with...
decompensation, can regress with proper treatment. Thus, finding effective therapies to prevent and reverse liver fibrosis is a tremendous medical challenge. Intracellular events and signals induce the activation of HSCs, the central driver of liver fibrogenesis, which makes them the potential targets for anti-fibrotic treatments. Our in vivo and in vitro studies showed that RSPO4-CRISPR effectively represses HSCs activation and relieves liver fibrosis in rats. These findings suggest RSPO4 could be a compelling target for early detection and therapy of liver fibrosis.

Studies indicate that liver disorders are accompanied by dysbiotic changes in gut microbiota. Thus, we hypothesized that the alteration of the gut microbiome would reflect the reversion of liver fibrosis as a consequence of controlling the underlying causes. Fecal samples from fibrotic-liver rats were analyzed by 16S rRNA sequencing. Results showed the fibrotic-liver rats have lower species richness and evenness than the normal rats, which was consistent with previous studies reporting that liver disease leads to gut microbiota dysbiosis. The community richness (Ace index) and diversity (Shannon index) of the fibrotic-liver rats increased significantly after receiving the RSPO4-CRISPR treatment (CRISPR group) were comparable to those of the model and negative group, and were nearly the same as the control. The taxonomic analysis presented a distinct difference in the gut microbiota community structure before and after the RSPO4-CRISPR medication. Further, PCoA analysis visualized the difference in bacteria composition between groups. The model group was obviously apart from the control, and the CRISPR group was intersected with the model group and the control. A similar pattern was also found in the enterotype analysis. Together, the above findings confirmed that the gut microbiome could reflect the reversion of liver fibrosis as a result of treatment with RSPO4-CRISPR.

To derive a panel of significant species for monitoring liver fibrosis and its regression to normal status, significant difference tests and LEfSe analyses were performed. In this context, data showed that Lactobacillus was predominant in the control group. This result was consistent with the previous report that Lactobacillus inhibits bacterial b-glucuronidase activity and associates with hepato-protection. Members of the genus Lactobacillus are the most abundant microbes in the mammalian gastrointestinal tract, and help to restore gut barrier integrity and maintain a healthy intestine. Numerous studies have indicated a probiotic role for Lactobacillus in the prevention and resolution of
infectious disease, which makes it an essential biomarker representing a healthy gut microbiome. This study found that Bacteroides and Escherichia–Shigella are significantly enriched in the fibrotic-liver rats. Bacteroides species are opportunistic human pathogens and can cause life-threatening infections including bacteremia. Previous studies reported that Bacteroides species are associated with a high-fat diet, and its abundance is significantly increased in nonalcoholic steatohepatitis, which is consistent with our data. Similarly, members of Escherichia–Shigella are also potential opportunistic pathogens that cause a spectrum of diseases, including diarrhea, and are a significant cause of mortality and morbidity worldwide. Notably, our study also indicates that genera belonging to Ruminococcaceae and Ruminococcus are specific to rats treated with RSPO4-CRISPR. Reports link Ruminococcaceae to a healthy liver status and negatively associate it with injury-related factors. Collectively, the indices of these significant species, such as the composition ratio and LDA index, may reflect the fibrotic status of the liver, and even its regression to the healthy status.

In conclusion, this study revealed that RSPO4 gene knockout with the CRISPR system relieves the liver fibrogenesis in rats, and restores dysbiotic gut microbiota related to liver fibrosis to an equilibrium status similar to healthy rats. Further, a panel of significant species was identified, which has the potential to serve as a surveillance index for the therapeutic effectiveness of liver fibrosis treatment. Finally, this group of significant species provides therapeutic targets for fecal microbiota transplantation treatment, which will require further studies.

**Fig. 6 Species that significantly differ between the CRISPR group, the model group, and the control.** A Circos analysis presented the distribution of the dominant species in the CRISPR group, the model group, and the control. B Kruskal–Wallis H test showed the abundance of several species were significantly different between the CRISPR group, the model group, and the control. Lactobacillus was significantly enriched in the control, Bacteroidales S24-7 group was high in the CRISPR group, and species Escherichia–Shigella, Bacteroides, and Collinsella were dominant in the model group. C The LEfSe results were aligned with those of the significant differences analysis between groups. Fecal samples were collected from 32 rats with CCl4-induced liver fibrosis and 20 normal rat (the control). Fecal samples collected before injection of RSPO4-CRISPR were noted as the model group, and samples collected after the injection of RSPO4-CRISPR were noted as the CRISPR group.
Animals used. Male Sprague-Dawley (SD) rats (8–10 weeks, 250–300 g) were purchased from Shanghai SLAC Laboratory Animal Co Ltd (Shanghai, China). The animals were housed under standard animal laboratory conditions and supplied with laboratory chow and water. All individuals involved in animal research received instructions in experimental methods and the care, maintenance, and handling of animals. All institutional and national guidelines for the care and use of laboratory animals were followed. The protocol of the experiments was approved by the Committee on the Ethics of Animal Experiments of Jiaxing College (JUMC2018-014).

Histopathology. The left lobe of the rat livers was fixed in 4% paraformaldehyde for at least 24 h, embedded in paraffin, and cut into 5-μm-thick sections. Following hydration in a decreasing ethanol gradient (100%, 95%, 70%, 50%, and pure water) for 5 min each, sections were deparaffinized and stained with H&E and Masson staining, Masson staining, western blot analysis, and PCR.

In vivo transduction of lentivirus. CCl4-induced liver-fibrotic rats were selected for injection of lentiviruses expressing RSPO4-CRISPR. In vivo transduction of lentiviruses (CRISPR-T3 and CRISPR-NC) was achieved through in situ injections of 30 μL of concentrated viral suspension with a viral titer of 1.0 × 10^8 TU/mL lentiviral particles in phosphate-buffered saline (PBS); injections were conducted three times of 30 μL. The injected viral suspensions were layered by Nycodenz (Sigma, United States) with a density gradient centrifugation according to manufacturer’s protocol. The resulting upper layer contained the isolated HSCs. The purity of isolated HSCs was examined by phase-contrast microscopy, and viability based on trypan blue exclusion (purity >95%, viability >95%). The isolated HSCs were then cultured on uncoated plastic plates in DMEM (Gibco, United States) supplemented with 10% FBS (Gibco, United States) at 37 °C at a density of 1 × 10^3 cells/cm^2 for future research. HSCs were co-cultured with a lentiviral vector (CRISPR-T1 and CRISPR-NC, MOI = 50). 48 h after infection, cells were harvested for further study.

Methods

In vivo injection of lentivirus vectors expressing RSPO4-CRISPR (CRISPR group), with cells isolated from normal rats served as the control. HSC activation status was tested by immunofluorescence, Oil red O staining, Transwell assay, and MTT.

Animals used. Male Sprague-Dawley (SD) rats (8–10 weeks, 250–300 g) were purchased from Shanghai SLAC Laboratory Animal Co Ltd (Shanghai, China). The animals were housed under standard animal laboratory conditions and supplied with laboratory chow and water. All individuals involved in animal research received instructions in experimental methods and the care, maintenance, and handling of animals. All institutional and national guidelines for the care and use of laboratory animals were followed. The protocol of the experiments was approved by the Committee on the Ethics of Animal Experiments of Jiaxing College (JUMC2018-014).

Histopathology. The left lobe of the rat livers was fixed in 4% paraformaldehyde for at least 24 h, embedded in paraffin, and cut into 5-μm-thick sections. Following hydration in a decreasing ethanol gradient (100%, 95%, 70%, 50%, and pure water) for 5 min each, sections were deparaffinized and stained with H&E and Masson staining, western blot analysis, and PCR.

In vivo transduction of lentivirus. CCl4-induced liver-fibrotic rats were selected for injection of lentiviruses expressing RSPO4-CRISPR. In vivo transduction of lentiviruses (CRISPR-T3 and CRISPR-NC) was achieved through in situ injections of 30 μL of concentrated viral suspension with a viral titer of 1.0 × 10^8 TU/mL lentiviral particles in phosphate-buffered saline (PBS); injections were conducted once. Three weeks after the dose, the animals were killed by CO2 exposure, and liver tissues were harvested.

HSC isolation and culture. Hepatic stellate cells were isolated from the livers of normal male SD rats (250–300 g of body weight), as previously described. In brief, rat liver was perfused in situ with Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, United States), dispersed cell suspensions were layered by Nycodenz (Sigma, United States) density gradient centrifugation according to manufacturer’s protocol. The resulting upper layer contained the isolated HSCs. The purity of isolated HSCs was examined by phase-contrast microscopy, and viability based on trypan blue exclusion (purity >95%, viability >95%). The isolated HSCs were then cultured on uncoated plastic plates in DMEM (Gibco, United States) supplemented with 10% FBS (Gibco, United States) at 37 °C at a density of 1 × 10^3 cells/cm^2 for future research. HSCs were co-cultured with a lentiviral vector (CRISPR-T1 and CRISPR-NC, MOI = 50). 48 h after infection, cells were harvested for further study.

Immunofluorescence assays. Immunofluorescence was used to examine the expression of RSPO4 and fibrosis biomarkers. Cells were paraformaldehyde-fixed followed by permeabilization with 0.1% Triton X100 and blocked with 4% bovine serum albumin. Then cells were incubated with rabbit polyclonal antibody for RSPO4 (Abcam, USA), α-SMA (Abcam, USA), and collagen-1 (Abcam, USA) overnight at 4 °C. Cells were then incubated with HRP-conjugated rabbit IgG (CST, USA) for 1 h. Nuclei were stained with 4′,6-diamidino-2-phenylindole (Sigma-Aldrich, USA). Images were captured using an epifluorescence microscope (Olympus, Tokyo, Japan).

PCR. The mRNA level was quantified by real-time PCR (StepOne-Plus, Applied Biosystems, CA) per the manufacturer’s instructions. To minimize the problems associated with DNA contamination, primers were designed to span at least one intron in the genomic sequence. Primers used for amplification are listed in Table 2. Total RNA from the cells was isolated using Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. The quality of isolated RNA was assessed at absorbance ratios of A260/A280 (1.8–2.2) and A260/A230 (3.0–4.0) with a UV-1800 spectrophotometer (Shimadzu, Kyoto, Japan). Thermocycling conditions consisted of an initial step of 2 min at 50 °C, denaturation of 10 min at 95 °C, followed by 35–40 cycles at 95 °C for 30 s, 60 °C for 45 s, and 72 °C for 1 min and a final elongation step at 72 °C for 10 min. Each sample was analyzed in triplicate, with β-actin used for normalization. Comparative threshold (Ct) method was used for calculating the relative amount of mRNA of the sample compared with the control.

Western blotting. Protein fractions were extracted using the NE-PER Extraction Reagent Kit (Pierce, United States) according to the manufacturer’s instruction. The extracts were then subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis for protein separation and then electrothermally transferred to nitrocellulose membrane (Pierce, United States). After blocking by phosphate-buffered saline containing 5% fat-free milk, the nitrocellulose membranes were incubated with rabbit polyclonal antibody for RSPO4 (dilution, 1:1000; Abcam, USA), α-SMA (dilution, 1:300; Abcam, USA), collagen-1 (dilution, 1:200; Abcam, USA), and β-Actin (dilution, 1:5000; Abcam, USA) overnight at 4 °C and then incubated with HRP-conjugated rabbit IgG (CST, USA) for 1.5 h at room temperature. The immunolabeled proteins were detected using a commercial ECL detection kit (HarO, Shanghai, China).

Lipid droplet analysis. Accumulations of lipid droplets in HSCs were determined using an Oil red O assay. In brief, 0.5 g of Oil red O powder (American Mastertech...
chamber at a density of 2 × 10^5 cells per well. The bottom chamber was pre-balanced of the Transwell chamber was performed by adding DMEM without FBS into the upper and bottom chamber overnight at 37°C. HSCs were trypsinized and suspended in 200 µl serum-free medium and were seeded in the upper chamber at a density of 2 × 10^5 cells per well. The bottom chamber was filled with DMEM containing 10% FBS. Following incubation for 24 h at 37°C. Migrated cells were then dried, fixed with methanol, and stained with 0.1% crystal violet at room temperature for 10 min. The transmembrane cells were counted using a light microscope (OLYMPUS BX43, Olympus Co., Japan) under x100 magnification.

**Table 1 sgRNA sequences.**

| Name       | Target                           | sgRNA                |
|------------|----------------------------------|----------------------|
| CRISPR-T1  | GGCTCTCAATTGTCCTTCAACATC          | caccGGCTCTCAATTGTCCTTCAACATC|
| CRISPR-T2  | GAGCAGGAAACGATTGGT               | caccGAGCAGGAAACGATTGGT|
| CRISPR-T3  | GCTTAAACAGATGACCTTTA             | caccGCTTAAACAGATGACCTTTA|

**Table 2 Primer sequences.**

| Gene       | Forward sequence                  | Reverse sequence     |
|------------|-----------------------------------|----------------------|
| Rspo4      | 5'-ATTCTGCTGAGGAGGAAACCAGC-3'     | 5'-CTCCTGACACTTGTTGAGCAGA-3'|
| α-SMA      | 5'-CTGACAGGACCCATGGA-3'           | 5'-CATCTCCAGATGCCAGACA-3'|
| Collagen-1 | 5'-TTCACTCACCACGCGTGTG-3'         | 5'-GATGACTCGTCTTGGCCCAAAGTT-3'|
| β-actin    | 5'-TCTCACTCTATTGGCAACAGGC-3'      | 5'-AACATGCCGCTTAAAGAACCC-3'|

**HSC migration assay.** A 24-well Transwell chamber with 8.0 µm pore size (Costar; Corning Incorporated, Corning, NY, USA) was used for the migration assay. The pre-balance of the Transwell chamber was performed by adding DMEM without FBS into the upper and bottom chamber overnight at 37°C. HSCs were trypsinized and suspended in 200 µl serum-free medium and were seeded in the upper chamber at a density of 2 × 10^5 cells per well. The bottom chamber was filled with DMEM containing 10% FBS. Following incubation for 24 h at 37°C, Migrated cells were then dried, fixed with methanol, and stained with 0.1% crystal violet at room temperature for 10 min. The transmembrane cells were counted using a light microscope (OLYMPUS BX43, Olympus Co., Japan) under x100 magnification.

**HSC invasion assay.** HSCs were seeded in a six-well Bio Coat Matrigel Invasion Chamber (Becton-Dickinson, Bedford, MA, USA) at a density of 2 × 10^5 cells per well. The bottom chamber was filled with DMEM containing 10% FBS. Following incubation for 24 h at 37°C, the non-invading cells were removed from the upper surface of the membrane by soft scratch with small cotton swabs. The membrane was then fixed with 4% Paraformaldehyde for 15 min and stained with 0.1% crystal violet at room temperature for 10 min. The invading cells were counted using a light microscope (OLYMPUS BX43, Olympus Co., Japan) under x100 magnification.

**MTT cell proliferation assay.** HSC proliferation was analyzed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation assay. HSCs were seeded into 96-well plate at the density of 2.0 × 10^3 per well. Cell growth was measured by MTT assay at the 6 h, 12 h, 24 h, 48 h, and 72 h after cell seeding. In brief, 100 µg of MTT (Sigma, United States) was added into each well. After incubation for 4 h at 37°C, purple formazan crystals were generated from viable cells were dissolved by adding 100 µl DMSO (Sigma-Aldrich, USA) in each well. The absorbance of each well was then read at 570 nm wavelength in Bio-Rad 550 microplate reader (Bio-Rad, United States). HSCs growth rates were then calculated as in Eq. 1.

$$\text{Cell growth rate} = \left( \frac{\text{average absorbance of test group}}{\text{control group}} \right) \times 100\%$$  

**Fecal sample collection.** Rats were transferred to a second home cage for the collection of fecal pellets. Fecal pellets were collected, flash-frozen, and stored at −80°C for later analysis.

**DNA extraction and 16 S rRNA gene amplicon sequencing.** Fecal microbial DNA was extracted from 250 mg frozen sample using Power Fecal DNA Kit (QiAamp, Germantown, MD, USA) following the manufacturer’s instructions. The final DNA concentration and purification were determined by NanoDrop 2000 UV-vis spectrophotometer (Thermo Scientific, Wilmington, USA), and DNA quality was checked by 1% agarose gel electrophoresis. The extracted DNA was stored at −20°C for future processing. The amplicon library was constructed by amplifying the V3/V4 region of 16 S rRNA gene using the primer 338F_806 R (338F: 5'–A CCTCTACGGGAGGCAGCAG-3' 806R: 5'-GGACTACHVGGGTWTCTAAT-3'). PCR was performed by thermocycler PCR system (GeneAmp 9700, ABI, USA) with TransStartFastp DNA Polymerase AP221-02 by using the following conditions: 95°C for 3 min followed by 30 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 45 s, and a final extension step at 72°C for 8 min. The PCR products amplicons are quantified using QuantiFluor™-ST (Promega, United States) according to the manufacturer’s protocol. Purified DNA samples were paired-end (PE300, 2x300 bp) sequenced by using Illumina MiSeq. Unqualified reads were removed to obtain clean data for further analysis. After clustering operational taxonomic units (OTU) at 97% identity, a total of 1971 OTUs were recovered from the fecal samples.

**16 S rRNA sequence analysis.** The sequenced 16 S reads were analyzed by using the QiIME software package90, the R programming language (R version 3.5.1), and the Python programming language (Python version 3.6). Data decontamination was performed using FLASH91 and Trimmomatic90. OTUs were created by clustering the reads at similarity threshold of 97% using Usearch (version 7.0, http://drive5.com/uparse/). The taxonomy of each OTU representative sequence was analyzed by RDP Classifier (http://rdp.cme.msu.edu/) against the Bacteria and archaea 16 S rRNA gene databases Silva (Release128 http://www.arb-silva.de) using confidence threshold of 0.7. Indexes of α-diversity were calculated using mothur (version v.1.35.1 https://www.mothur.org/).

Circos plot was drawn by Circos-0.67.7 (http://circos.ca/), and a phylogenetic tree was inferred by using FastTree (version 2.1.3 http://www.microbesonline.org/fasttree). Principal component analysis and PCA analysis (Principal coordinates analysis) were performed by using R and python for analysis and plotting. With R Ade4 and cluster, enterotyping analysis calculated Jensen-Shannon Distance and PAM (Partitioning Around Medoids) according to the relative abundance of the species level first and then do clustering. Differences analysis was performed by using R for significant difference between groups (Kruskal–Wallis H tests) and Galaxy (http://butlerhower.sph.harvard.edu/galaxy/) for LEfSe.

**Statistical analysis.** All statistical analyses were performed using R software (version 3.5.1). Data were presented as mean ± SEM. A value of p < 0.05 was considered to be statistically significant. A two-tailed Student’s t test was employed to evaluate the differences between groups. For semi-quantitative analysis of histological staging, nonparametric tests (Mann–Whitney U test or Kruskal–Wallis rank-sum test) were used.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**

Source data that support the findings in our study are available upon reasonable request to the corresponding authors. In all, 16 S rRNA sequence data can be accessed from NCBI BioProject under identifier PRJNA543718. Original gel images corresponding to Fig. 1d are available in Supplementary Figure 2.

**Code availability**

Our analysis used standard, open source software. R packages are available on CRAN (cran.r-project.org), Galaxy (usegalaxy.org), and the Python programming language (Python version 3.6).
References

1. Friedman, S. L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655–1669 (2008).

2. Friedman, S. L. Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. Hepatol. 7, 425–436 (2010).

3. Trautwein, C. et al. Hepatic fibrosis: concept to treatment. J. Hepatol. 62, S15–S24 (2015).

4. Schuppan, D. & Afdhal, N. H. Liver cirrhosis. Lancet 371, 838–851 (2008).

5. Tschoatzis, E. A., Bosch, J. & Burroughs, A. K. Liver cirrhosis. Lancet 383, 1749–1761 (2014).

6. Forner, A., Reig, M. & Bruix, J. Hepatocellular carcinoma. Lancet 391, 1301–1314 (2018).

7. Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Cell Metab. 17, 2044–2056 (2013).

8. Schnabl, B. & Brenner, D. A. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 146, 1513–1524 (2014).

9. Ma, C. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360, 6391 (2018).

10. Tilg, H., Cani, P. D. & Mayer, E. A. Gut microbiome and liver diseases. Gut 65, 2035–2044 (2016).

11. Monga, S. P. beta-catenin signaling and roles in liver homeostasis, injury, and tumorgenesis. Gastroenterology 148, 1294–1310 (2015).

12. Acharya, C., Sahingur, S. E. & Bajaj, J. S. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. ICI Insight. 2, 19 (2017).

13. Hold, G. L. et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?. World J. Gastroenterol. 20, 1192–1210 (2014).

14. Mayer, E. A., Tillisch, K. & Gupta, A. Gut/brain axis and the microbiota. Nat. Rev. Gastroenterol. Hepatol. 10, 696–711 (2013).

15. Safari, Z. & Gerard, P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol. Life Sci. 76, 1541–1558 (2019).

16. Seki, E. Microbiome-obesity-liver cancer interaction: senescence of hepatic stellate cells and bile acids play new roles. Gastroenterology 146, 860–861 (2014).

17. Shackle, N. A. et al. Beyond liver fibrosis: hepatic stellate cell senescence links obesity to liver cancer by way of the microbiome. Hepatology 59, 2413–2415 (2014).

18. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).

19. Cong, L. & Zhang, F. Genome engineering using CRISPR-Cas9 system. Methods Mol. Biol. 1239, 197–217 (2015).

20. Dominguez, A. A., Lim, W. A. & Qi, L. S. Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat. Rev. Mol. Cell Biol. 17, 5–15 (2016).

21. Gilbert, L. A. et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647–661 (2014).

22. Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583–588 (2015).

23. Ellis, E. L. & Mann, D. A. Clinical evidence for the regression of liver fibrosis. J. Hepatol. 56, 1171–1180 (2012).

24. Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381, 468–475 (2013).

25. Kissela, T. et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc. Natl Acad. Sci. USA 109, 9448–9453 (2012).

26. Troeger, J. S. et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology 143, 1073–1083 (2012), e22.

27. Boursier, J. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63, 764–775 (2016).

28. Boursier, J. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63, 764–775 (2016).

29. Yip, L. Y. et al. The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat. Hepatology 67, 282–295 (2018).

30. Jang, Y. J. et al. Lactobacillus fermentum species ameliorate dextran sulfate sodium-induced colitis by regulating the immune response and altering gut microbiota. Gut Microbes 10, 696–711 (2019).

31. Heeney, D. D., Garea, M. G. & Marco, M. L. Intestinal Lactobacillus in health and disease, a driver or just along for the ride?. Curr. Opin. Biotechnol. 49, 140–147 (2018).

32. Wexler, H. M. Bacteroides: the good, the bad, and the nitty-gritty. Clin. Microbiol. Rev. 20, 593–621 (2007).

33. Khalil, I. A. et al. Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhea: the Global Burden of Disease Study 1990–2016. Lancet Infect. Dis. 18, 1229–1240 (2018).

34. Kakiyama, G. et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J. Hepatol. 58, 949–953 (2015).

35. Bajaj, J. S. et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial. Hepatology 70, 1690–1703 (2019).

36. Wu, W. et al. Protective effect of akkermansia muciniphila against immune-mediated liver injury in a mouse model. Front. Microbiol. 8, 1804 (2017).

37. Ramm, G. A. Isolation and culture of rat hepatic stellate cells. J. Gastroenterol. Hepatol. 13, 846–851 (1998).

38. Lawley, B. & Tannock, G. W. Analysis of 16S RNA gene amplicon sequences using the QIIME software package. Methods Mol. Biol. 1537, 153–163 (2017).

39. Magoc, T. & Salzberg, S. L. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 27, 2957–2963 (2011).

40. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics 30, 2114–2120 (2014).

Acknowledgements

This work was supported by grants from the Natural Science Foundation of Zhejiang Province (LY16H030016, LY17H030012). Key medical discipline in jiaxing—Gastroenterology (2019-ZC-08).

Author contributions

Linghua Yu participated in the design, data analysis, and interpretation, and drafted the manuscript. Linlin Wang, Huixing Yi, and Xiaojun Wu participated in the interpretation of experiments and helped to finalize the paper.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s42003-021-01747-5.

Correspondence and requests for materials should be addressed to L.Y.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021